| Primary |
| Sepsis |
15.9% |
| Convulsion |
8.9% |
| Pyrexia |
7.0% |
| Infection |
6.4% |
| Pneumonia |
6.4% |
| Brain Abscess |
5.7% |
| Cerebral Haemorrhage |
5.1% |
| Urinary Tract Infection |
4.5% |
| Bacterial Sepsis |
3.8% |
| Bronchopneumonia |
3.8% |
| Febrile Neutropenia |
3.8% |
| Pneumonitis |
3.8% |
| Postoperative Wound Infection |
3.8% |
| Respiratory Tract Infection |
3.8% |
| Staphylococcal Infection |
3.8% |
| Atrial Fibrillation |
3.2% |
| Cystic Fibrosis |
3.2% |
| Encephalitis |
2.5% |
| Pseudomonas Infection |
2.5% |
| Abdominal Abscess |
1.9% |
|
| Convulsion |
8.4% |
| Death |
8.4% |
| Drug Interaction |
8.4% |
| Skin Exfoliation |
8.4% |
| Renal Failure Acute |
7.2% |
| Stevens-johnson Syndrome |
7.2% |
| Infection |
4.8% |
| Neutropenia |
4.8% |
| Rash Maculo-papular |
4.8% |
| Thrombocytopenia |
4.8% |
| Tooth Discolouration |
4.8% |
| Tremor |
4.8% |
| Cardiac Arrest |
3.6% |
| Deafness |
3.6% |
| Rash |
3.6% |
| Accidental Overdose |
2.4% |
| Drug Ineffective |
2.4% |
| Electrolyte Imbalance |
2.4% |
| Eosinophil Count Increased |
2.4% |
| Grand Mal Convulsion |
2.4% |
|
| Secondary |
| Sepsis |
17.6% |
| Pyrexia |
13.2% |
| Product Used For Unknown Indication |
9.8% |
| Convulsion |
7.3% |
| Febrile Neutropenia |
6.8% |
| Antibiotic Prophylaxis |
6.3% |
| Pneumonia |
5.9% |
| Urinary Tract Infection |
5.9% |
| Cystic Fibrosis |
5.4% |
| Encephalitis |
2.9% |
| Infection |
2.4% |
| Klebsiella Sepsis |
2.4% |
| Antifungal Prophylaxis |
2.0% |
| Atrial Fibrillation |
2.0% |
| Bronchitis |
2.0% |
| Bronchopneumonia |
2.0% |
| Computerised Tomogram |
2.0% |
| Blood Cholesterol Increased |
1.5% |
| Chemotherapy |
1.5% |
| Contraception |
1.5% |
|
| Deafness |
15.7% |
| Rash Generalised |
11.8% |
| Skin Exfoliation |
9.8% |
| Cardiac Arrest |
7.8% |
| Leukocytoclastic Vasculitis |
5.9% |
| Platelet Count Decreased |
5.9% |
| Convulsion |
3.9% |
| Death |
3.9% |
| Electrolyte Imbalance |
3.9% |
| Heart Rate Increased |
3.9% |
| Hypocoagulable State |
3.9% |
| Rash Macular |
3.9% |
| Rash Maculo-papular |
3.9% |
| Rhabdomyolysis |
3.9% |
| Angioedema |
2.0% |
| Bone Marrow Failure |
2.0% |
| Bradycardia |
2.0% |
| Cholestasis |
2.0% |
| Device Malfunction |
2.0% |
| Drug Interaction |
2.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
52.7% |
| Drug Use For Unknown Indication |
16.9% |
| Pain |
4.4% |
| Nausea |
3.2% |
| Prophylaxis Against Transplant Rejection |
3.2% |
| Prophylaxis |
2.9% |
| Anxiety |
2.1% |
| Pyrexia |
2.1% |
| Vomiting |
1.7% |
| Bronchopneumonia |
1.5% |
| Constipation |
1.2% |
| Infection Prophylaxis |
1.2% |
| Acute Myeloid Leukaemia |
1.0% |
| Anaphylaxis Prophylaxis |
1.0% |
| Infection |
0.9% |
| Pneumonia |
0.9% |
| Diarrhoea |
0.8% |
| Atrial Fibrillation |
0.8% |
| Contraception |
0.8% |
| Non-small Cell Lung Cancer |
0.8% |
|
| Thrombocytopenia |
12.3% |
| Sepsis |
9.9% |
| Cholelithiasis |
7.4% |
| Acute Myeloid Leukaemia |
4.9% |
| Gastrointestinal Perforation |
4.9% |
| Hepatitis Acute |
4.9% |
| Hyperamylasaemia |
4.9% |
| Pericarditis |
4.9% |
| Pyrexia |
4.9% |
| Septic Shock |
4.9% |
| Abdominal Pain |
3.7% |
| Anaemia |
3.7% |
| Erythema |
3.7% |
| Febrile Neutropenia |
3.7% |
| Platelet Count Decreased |
3.7% |
| Pneumonia |
3.7% |
| Renal Failure Acute |
3.7% |
| Tongue Discolouration |
3.7% |
| White Blood Cell Count Decreased |
3.7% |
| Cerebral Haemorrhage |
2.5% |
|
| Interacting |
| Convulsion |
60.0% |
| Infection |
20.0% |
| Epilepsy |
10.0% |
| Sepsis |
10.0% |
|
| Drug Interaction |
66.7% |
| Anticonvulsant Drug Level Decreased |
33.3% |
|
